Home › Compound Library › Insulin Glargine (Lantus)

Insulin Glargine (Lantus)

Hormoneprescriptionsubcutaneous · inferred

Long-acting basal insulin analog with a relatively flat, peakless pharmacokinetic profile providing ~24h coverage. Acidic solution (pH 4.0) forms microprecipitate at subcutaneous tissue pH (7.4), enabling slow release from depot. Once-daily injection.

Projected serum levels — 30 units (≈ 1.0 mg), once daily

Insulin Glargine (Lantus)
Insulin Glargine (Lantus) modeled serum levels, 30 units (≈ 1.0 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Insulin Glargine (Lantus) modeled serum levels with a loading dose of 49.6 units, then 30 units (≈ 1.0 mg) once daily The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 30 units (≈ 1.0 mg) once daily (subcutaneous).

Loading schedule: 49.6 units on day 1, then 30 units (≈ 1.0 mg) once daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 0.86 mg, trough ≈ 0.55 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Hormone
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
12 h
Common dose
30 units (≈ 1.0 mg)
Suggested maximum
100 units/day
Reference dose range
10–100 units (single dose)
Suggested cadence
once daily

Documented interactions

  • moderate
    Insulin Aspart (NovoLog) + Insulin Glargine (Lantus) Stacked effects

    Insulin Aspart (NovoLog) and Insulin Glargine (Lantus) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin Lispro (Humalog) + Insulin Glargine (Lantus) Stacked effects

    Insulin Glargine (Lantus) and Insulin Lispro (Humalog) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin NPH (Humulin N) + Insulin Glargine (Lantus) Stacked effects

    Insulin Glargine (Lantus) and Insulin NPH (Humulin N) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin Regular (Humulin R) + Insulin Glargine (Lantus) Stacked effects

    Insulin Glargine (Lantus) and Insulin Regular (Humulin R) both push the igf1 receptor and insulin receptor in the same direction.

Serum checks 4 modeled interaction pairings for insulin glargine (lantus) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia (ORIGIN) Gerstein HC et al. · New England Journal of Medicine, 2012 DOI

    Landmark 12,537-patient trial finding that insulin glargine maintained normoglycemia over 6.2 years with neutral cardiovascular effect and no increase in cancer, establishing long-term safety of basal insulin in…

  2. The Treat-to-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients Riddle MC et al. · Diabetes Care, 2003 DOI

    Pivotal treat-to-target trial showing insulin glargine achieved equivalent HbA1c reduction to NPH but with significantly less nocturnal hypoglycemia, establishing glargine as preferred basal insulin for type 2 diabetes.

  3. Less Nocturnal Hypoglycemia and Better Post-Dinner Glucose Control with Bedtime Insulin Glargine Compared with Bedtime NPH Insulin during Insulin Combination Therapy in Type 2 Diabetes Yki-Järvinen H et al. · Diabetes Care, 2000 DOI

    Demonstrated that bedtime glargine reduced nocturnal hypoglycemia by 44% vs NPH while providing better post-dinner glucose control, confirming the clinical advantage of glargine's flat pharmacokinetic profile.

3 published studies referenced in the app, each with a plain-language summary.